Elevated Serum Neuropeptide FF Levels Are Associated with Cognitive Decline in Patients with Spinal Cord Injury.

Publisher: Hindawi Pub. Corp Country of Publication: United States NLM ID: 8604127 Publication Model: eCollection Cited Medium: Internet ISSN: 1875-8630 (Electronic) Linking ISSN: 02780240 NLM ISO Abbreviation: Dis Markers Subsets: MEDLINE

Publication: 2015- : New York, NY : Hindawi Pub. Corp.
Original Publication: Chichester ; New York : Wiley, c1983-

Biomarkers/*blood ; Cognitive Dysfunction/*diagnosis ; Oligopeptides/*blood ; Spinal Cord Injuries/*complications; Case-Control Studies ; Cognitive Dysfunction/blood ; Cognitive Dysfunction/etiology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Prognosis ; Prospective Studies

Background: Spinal cord injury (SCI) has high incidence globally and is frequently accompanied by subsequent cognitive decline. Accurate early risk-categorization of SCI patients for cognitive decline using biomarkers can enable the timely application of appropriate neuroprotective measures and the development of new agents for the management of SCI-associated cognitive decline. Neuropeptide FF is an endogenous neuropeptide with a multitude of functions and is associated with neuroinflammatory processes. This prospective study investigated the predictive value of serum neuropeptide FF levels measured after acute SCI for subsequent cognitive decline.
Methods: 88 patients presenting with acute SCI without preexisting neurological injury, brain trauma, or severe systemic illness and 60 healthy controls were recruited. Serum neuropeptide FF levels, clinical, and routine laboratory variables including low-density lipoprotein, high-density lipoprotein, fasting blood glucose, total triiodothyronine (TT3), total thyroxine (TT4), and thyroid-stimulating hormone (TSH) levels collected from all subjects were assessed. Montreal cognitive assessment (MoCA) was performed 3 months after enrollment. SCI patients were grouped according to quartile of serum neuropeptide FF level and MoCA scores were compared using ANOVA. Additionally, multivariate linear regression with clinical and laboratory variables was performed to predict MoCA scores.
Results: SCI patients displayed significantly higher baseline serum neuropeptide FF levels than healthy controls (38.5 ± 4.1 versus 23.4 ± 2.0 pg/ml, p < 0.001 ^∗∗ ). SCI patients in higher quartiles of baseline serum neuropeptide FF displayed significantly lower MoCA scores at 3 months. Linear regression analysis indicated serum neuropeptide FF levels as a significant independent predictor of worse MoCA scores after SCI ( r = 0.331, p = 0.034 ^∗ ).
Conclusion: Early serum neuropeptide FF levels significantly and independently predicted cognitive decline after acute SCI among patients without preexisting neurological disorders.
Competing Interests: The authors report no conflict of interest.
(Copyright © 2021 Shifei Sun et al.)

Neuroscience. 2009 Sep 15;162(4):1220-31. (PMID: 19447162)
J Neuroinflammation. 2016 Oct 6;13(1):260. (PMID: 27716334)
Brain. 2006 Mar;129(Pt 3):718-28. (PMID: 16330503)
BMC Psychiatry. 2012 Sep 25;12:156. (PMID: 23009126)
Am J Phys Med Rehabil. 1998 Mar-Apr;77(2):108-12. (PMID: 9558010)
Mol Neurobiol. 2018 Aug;55(8):6436-6448. (PMID: 29307082)
J Am Geriatr Soc. 2005 Apr;53(4):695-9. (PMID: 15817019)
J Spinal Cord Med. 2007;30(5):477-81. (PMID: 18092564)
Int J Mol Sci. 2017 Aug 21;18(8):. (PMID: 28825666)
J Neurotrauma. 2017 Mar 15;34(6):1156-1163. (PMID: 27717295)
J Biol Chem. 2000 Dec 15;275(50):39324-31. (PMID: 11024015)
Neurorehabil Neural Repair. 2020 Feb;34(2):95-110. (PMID: 31971869)
Front Endocrinol (Lausanne). 2013 Feb 07;4:8. (PMID: 23404625)
Int J Mol Sci. 2021 Jul 16;22(14):. (PMID: 34299230)
J Spinal Cord Med. 2020 Jan;43(1):88-97. (PMID: 30508409)
Nat Rev Neurol. 2021 Jan;17(1):53-62. (PMID: 33311711)
Neurology. 2018 Sep 25;91(13):611-621. (PMID: 30158159)
Peptides. 2017 Feb;88:189-195. (PMID: 28062253)
Peptides. 2011 Apr;32(4):702-6. (PMID: 21167893)
Eur Spine J. 2015 May;24(5):905-18. (PMID: 24952008)
Spinal Cord. 2004 Jun;42(6):359-67. (PMID: 15007376)
J Clin Endocrinol Metab. 2007 Jul;92(7):2439-45. (PMID: 17426095)
Sci Bull (Beijing). 2021 Aug 30;66(16):1684-1690. (PMID: 36654302)
J Int Neuropsychol Soc. 1997 Sep;3(5):464-72. (PMID: 9322406)
Curr Gerontol Geriatr Res. 2008;:474868. (PMID: 19415145)
Br J Pharmacol. 2016 Feb;173(4):681-91. (PMID: 25939377)
Curr Hypertens Rep. 2017 Mar;19(3):24. (PMID: 28299725)
Chin J Physiol. 2019 Mar-Apr;62(2):47-52. (PMID: 31243174)
J Pharmacol Exp Ther. 2010 Jul;334(1):244-54. (PMID: 20354177)
Front Mol Neurosci. 2015 Dec 09;8:73. (PMID: 26696821)
J Neurosci. 2014 Aug 13;34(33):10989-1006. (PMID: 25122899)
Prog Neurobiol. 1996 Mar-Apr;48(4-5):461-87. (PMID: 8804117)
Neuroscience. 2019 Sep 15;416:281-293. (PMID: 31421202)
FEBS Lett. 2002 Dec 18;532(3):313-8. (PMID: 12482585)
Lancet Neurol. 2013 Sep;12(9):873-881. (PMID: 23827394)
Invest Ophthalmol Vis Sci. 2015 Dec;56(13):7754-65. (PMID: 26641552)
J Am Geriatr Soc. 1999 Feb;47(2):159-64. (PMID: 9988286)
Neuroimage Clin. 2018 Aug 19;20:556-563. (PMID: 30175042)
Arch Neurol. 1986 May;43(5):501-4. (PMID: 2870700)
Peptides. 1998;19(7):1165-70. (PMID: 9786165)
Ann Neurol. 2015 Nov;78(5):751-61. (PMID: 26290444)
J Med Chem. 2020 Nov 12;63(21):12387-12402. (PMID: 32673481)
Atherosclerosis. 2009 Oct;206(2):528-34. (PMID: 19349048)
Lancet Neurol. 2006 Aug;5(8):688-94. (PMID: 16857574)
Arch Phys Med Rehabil. 2021 Mar;102(3):431-439. (PMID: 32739506)
Neurology. 2018 Apr 3;90(14):e1257-e1266. (PMID: 29514946)
Front Aging Neurosci. 2020 Feb 05;11:370. (PMID: 32116643)
Mol Neurobiol. 2018 Mar;55(3):2174-2184. (PMID: 28290147)
Peptides. 2000 Nov;21(11):1695-701. (PMID: 11090924)
Arch Phys Med Rehabil. 2008 Dec;89(12 Suppl):S77-84. (PMID: 19081445)
J Neurotrauma. 2016 Nov 1;33(21):1919-1935. (PMID: 27050417)
Brain Res. 2004 Sep 10;1020(1-2):37-44. (PMID: 15312785)
Peptides. 1995;16(2):347-50. (PMID: 7784266)
Peptides. 2012 Nov;38(1):110-7. (PMID: 22981806)
World Neurosurg. 2018 May;113:e345-e363. (PMID: 29454115)
Front Cell Neurosci. 2018 Jun 07;12:158. (PMID: 29930500)
Curr Opin Neurobiol. 2016 Feb;36:74-81. (PMID: 26517285)
J Neurotrauma. 2011 Apr;28(4):619-34. (PMID: 21265596)
J Spinal Cord Med. 2013 Mar;36(2):74-81. (PMID: 23809520)
Peptides. 1997;18(2):287-92. (PMID: 9149302)

0 (Biomarkers)
0 (Oligopeptides)
99566-27-5 (phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide)

Date Created: 20211122 Date Completed: 20220301 Latest Revision: 20240404

20240404

PMC8601828

10.1155/2021/4549049

34804262